Novo Nordisk to invest $65mn into diabetes care manufacturing site expansion

The Danish diabetes care firm, Novo Nordisk, has announced its plans to expand its drug manufacturing facility in Clayton, North Carolina.

The company aims to invest $65mn into the facility on its Johnston County campus, which works with formulating, filling, inspecting, assembling, and packaging diabetes and obesity medicine.

“We’re pleased to call Johnston County our home, and greatly appreciate the trust and partnership the Board of Commissioners and community have given us,” commented the Corporate Vice President and General Manager of Clayton’s Diabetes Finished Products Facility, Chad Henry.

“The inspiration that drives us to provide innovative care for our patients is matched by our enduring commitment to bringing jobs and economic growth to our community.”

SEE ALSO:

• Amgen to develop a $300mn biomanufacturing facility

• Accord Healthcare opens new pharmaceutical facility in Newcastle

• UD starts construction on Biopharmaceutical Innovation Building at STAR campus

• Read the latest issue of Manufacturing Global here

The site currently employs more than 1,000 workers, says the Johnston County Economic, an intends to hire a further 24 members of staff following the expansion.

“Johnston County is proud to have been part of Novo Nordisk’s growth and success for the past 25 years, and today’s announcement underscores our place at the heart of the company’s global business strategy,” reported Jeffrey Carver, Chairman of the Johnston County Board of Commissioners.

The county board agreed to support the extension unanimously, offering up to $1.9mn in grants based on performance over a 13-year period.